other:Article Title: H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer
Article Snippet: The primary antibodies consisted of: SETDB1 (Proteintech, 11231-1-AP), SUV39H1 (Cell Signaling, #8729), SUV39H2 (Abcam, #ab190870), EHMT1 (Bethyl Laboratories, #A301-642A), EHMT2 (Proteintech, #66689-1-Ig; Cell Signaling, #3306), KDM3A (Proteintech, #12835-1-AP), KDM4A (Bethyl Laboratories, #A300-861A), KDM4B (Bethyl Laboratoris, #A301-478A), CBX1 (Cell Signaling, #8676), CBX3 (Cell Signaling, #2619), CBX5 (Cell Signaling, #2616), MeCP2 (Cell Signaling, #3456), GR (BD Biosciences, #611227), pSTAT1 pY701(Cell Signaling, #9167), pSTAT3 pY705(Cell Signaling, #9145), pSTAT3 pS727(Cell Signaling, #9134), pTBK1 pS172 (Cell Signaling, #5483; Abcam, #ab109272), pIRF3(Cell Signaling, #37829), MAVS(Cell Signaling, #24930), ISG15 (Proteintech, #15981-1-AP), IFIT1 (Proteintech, #23247-1-AP), IFNB1 (Cell Signaling, #73671, PSA (Cell Signaling, #5361), ADAR1 (Cell Signaling #8124) ACTB (Cell Signaling, #2409), GAPDH (Cell Signaling, #2118), cyclophilin B (Cell Signaling, #43603), histone H3 (Abcam, #ab1791; Cell Signaling, #4499), H3K9me1(Abcam, #ab8896), H3K9me2(Cell Signaling, #4658), H3K9me3 (Abcam, #8898; Active Motif, #39062), H3K9ac (Cell Signaling, #9649), H3K9M (Cell Signaling, #78087).
|